← Back to home

HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) AND DIABETES MELLITUS, TYPE 2

Clinical trials for HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) AND DIABETES MELLITUS, TYPE 2 explained in plain language.

Never miss a new study

Get alerted when new HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) AND DIABETES MELLITUS, TYPE 2 trials appear

Sign up with your email to follow new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) AND DIABETES MELLITUS, TYPE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Weekly shot shows promise for easing heart failure and shedding pounds

Disease control Completed

This study tested whether a weekly injection of the medicine semaglutide could improve daily life and reduce body weight for people living with a specific type of heart failure and type 2 diabetes. Over 600 participants were randomly assigned to receive either the real medicine o…

Matched conditions: HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) AND DIABETES MELLITUS, TYPE 2

Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control

Last updated Apr 02, 2026 07:26 UTC

HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) AND DIABETES MELLITUS, TYPE 2

Get alerted when new HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) AND DIABETES MELLITUS, TYPE 2 trials appear

Weekly shot shows promise for easing heart failure and shedding pounds